Juslina DM 10mg/5mg/500mg Tablet is a fixed-dose combination medication containing Dapagliflozin 10mg, Linagliptin 5mg, and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. This combination targets multiple pathophysiological defects of diabetes to improve glycemic control. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The synergistic action of these agents offers effective glycemic control with a reduced risk of hypoglycemia. Juslina DM is typically prescribed as an adjunct to diet and exercise in patients inadequately controlled on monotherapy or dual therapy. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, urinary tract infections, and potential risk of lactic acidosis. Regular monitoring of renal function, blood glucose, and HbA1c is recommended during therapy. Juslina DM should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.